Library Subscription: Guest
International Journal of Medicinal Mushrooms

Published 12 issues per year

ISSN Print: 1521-9437

ISSN Online: 1940-4344

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.2 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 1.4 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00066 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.34 SJR: 0.274 SNIP: 0.41 CiteScore™:: 2.8 H-Index: 37

Indexed in

Medicinal Sulphur Polypore Mushroom Laetiporus sulphureus (Agaricomycetes) Plus Tiny Amounts of Essential Oils Decrease the Activity of Crohn Disease

Volume 21, Issue 3, 2019, pp. 267-273
DOI: 10.1615/IntJMedMushrooms.2019030122
Get accessGet access

ABSTRACT

A mixture of Laetiporus sulphureus (LS) and essential oils of Origanum vulgare, Cinnamomum verum, and Syzygium aromaticum (LOCS) was recommended for 24 patients with Crohn disease (CD). Patients were followed up for at least 24 months (median 32 months; range, 24-54 months). Nineteen patients were compliant with the treatment, although 3 stopped taking it, relapsed, began the LOCS regimen again, and recovered; 5 patients were not compliant at all. Compliant patients experienced flares of CD, with a CD Activity Index > 220, for 5.6% of the surveillance period (median 34 months). Noncompliant patients experienced flares of CD, with a CD Activity Index > 220, for 75.0% of the surveillance period (median 26 months; P < 10-6). Each case was then analyzed with a Bayesian approach that considered the probability of CD spontaneously disappearing within 2 weeks after intake of LOCS, the reappearance of CD within 2 weeks after stopping LOCS, and the disappearance of CD again after rechallenge. For the 19 compliant patients, the global posterior probability (probability that all the events observed were due to coincidence only) was equal to 10-6. Thus it can be concluded that LOCS decreases the CD Activity Index. Further investigations are necessary to unravel the mechanism of action of LOCS and to confirm its positive effect over periods as long as 5 to 10 years.

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain